BTIG reiterates Buy rating on CareDx stock, sees comeback in 2026

Investing.comTuesday, September 23, 2025 at 9:39:02 AM
BTIG reiterates Buy rating on CareDx stock, sees comeback in 2026
BTIG has reaffirmed its Buy rating on CareDx stock, projecting a significant recovery for the company in 2026. This is important as it reflects confidence in CareDx's future performance and potential growth, which could attract investors looking for promising opportunities in the healthcare sector.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Lytix Biopharma Q3 2025 slides: Ruxotemitide advances as cash runway extends to 2026
NeutralFinancial Markets
Lytix Biopharma reported advancements in its Ruxotemitide program during its Q3 2025 earnings call, indicating a positive trajectory for the company's product pipeline. The company also announced that its cash runway has been extended into 2026, providing a more stable financial outlook. This extension is crucial for supporting ongoing clinical trials and further development of its biopharmaceutical innovations.